Revive Therapeutics Ltd. | RVV Profile

Shares :

COMPANY PROFILE

REVIVE THERAPEUTICS LTD


SYMBOL :                                               RVV |  RVVTF

SECTOR :                                               LIFE SCIENCE

O/S :                                                        230 M

MARKET CAP :                                      $ 62 M

MARKET OPPORTUNITY :                   UP TO $350 B

REVIVE THERAPEUTICS LTD is as unique opportunity to invest in the next evolution of the psychedelic market with Cannabidiol and Bucillamine development

Huge upside potential VS peers

Revive Therapeutics Ltd.| RVV (CSE)  is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.

With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation

MAJOR DEVELOPMENT

REVIVE THERAPEUTICS Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19  | More info

COMPANY BRIEF

 

| Emerging cannabis and psychedelic life sciences company

| Developing novel cannabis and psychedelic based therapies to treat liver, inflammatory, and rare diseases

| Robust cannabis and psychedelic based product portfolio targeting multi-billion market opportunities

| Significantly undervalued compared to biopharma and psychedelics peers

| Unique opportunity to invest in the next evolution of the cannabis and psychedelic market

| They explore the use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

HIGHLIGHTS

 

| 4 Exclusive licenses to patents in delivery system and liver disease

| 2 FDA orphan drug designation for CBD in treatment of AIH and prevention IRI from solid organ transplantation

| Acquired Psilocin Pharma Corp. (PPC)

| Novel Psilocybin formulations, extraction and purification methods with Patent pending Psilocybin formulations

| Market opportunity up to $350 Billions

| Delivering naturally extracted and synthetic psilocybin and cannabinoids

| Advancing towards FDA Phase 3 clinical study for COVID-19

The psychedelic market worldwide is huge and valued at more than $350 billion according to analysts.

PHARMACEUTICAL STRATEGY

Pharma deals in liver diseases

| Allergan / Tobira: $ 1.7 Billions Acquisition
| Novartis / Conatus $ 650 Million License
| Gilead / Nimbus $ 1.2 Billions Acquisition

Pharma deals in skin diseases

| Purdue / Exicure $ 790 Million License
| Astra / Valeant $ 445 Million License
| Allergan / Vitae $ 639 Million Deal

STRATEGIC RELATIONSHIPS

UNDERVALUED VS PEERS

VALUE DRIVING MILESTONES IN 2020

Products Pipeline

RVV | CSE

RVV | OTC

JOIN FACEBOOK INVESTOR GROUP

Last REVIVE news

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Acquires Unique Psilocybin Assets

Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

A very promising new study for Bucillamine for the treatment of COVID-19.

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor


Shares :